PE20141972A1 - Inhibidores de la beta-secretasa - Google Patents
Inhibidores de la beta-secretasaInfo
- Publication number
- PE20141972A1 PE20141972A1 PE2014001347A PE2014001347A PE20141972A1 PE 20141972 A1 PE20141972 A1 PE 20141972A1 PE 2014001347 A PE2014001347 A PE 2014001347A PE 2014001347 A PE2014001347 A PE 2014001347A PE 20141972 A1 PE20141972 A1 PE 20141972A1
- Authority
- PE
- Peru
- Prior art keywords
- beta
- refers
- secretase inhibitors
- compounds
- secretase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/02—Thiocyanates
- C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
- C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ACILGUANIDINAS ESPIROCICLICAS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA ENZIMA BETA-SECRETASA (BACE1) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES QUE SE CARACTERIZAN POR LA PRODUCCION DE DEPOSITOS B-AMILOIDES O DE HACES NEUROFIBRILARES TALES COMO LA ENFERMEDAD DE ALZHEIMER, EL SINDROME DE DOWN, DEMENCIA SENIL, ANGIOPATIA AMILOIDE CEREBRAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606786P | 2012-03-05 | 2012-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141972A1 true PE20141972A1 (es) | 2014-12-28 |
Family
ID=47902355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001347A PE20141972A1 (es) | 2012-03-05 | 2013-03-04 | Inhibidores de la beta-secretasa |
Country Status (40)
Country | Link |
---|---|
US (4) | US8981112B2 (es) |
EP (1) | EP2822930B1 (es) |
JP (1) | JP6161643B2 (es) |
KR (1) | KR20140138774A (es) |
CN (1) | CN104271558B (es) |
AP (1) | AP4029A (es) |
AR (1) | AR090241A1 (es) |
AU (2) | AU2013230523B2 (es) |
BR (1) | BR112014021269A2 (es) |
CA (1) | CA2864143C (es) |
CL (1) | CL2014002334A1 (es) |
CO (1) | CO7091177A2 (es) |
CY (1) | CY1117543T1 (es) |
DK (1) | DK2822930T3 (es) |
EA (1) | EA024995B1 (es) |
EC (1) | ECSP14020640A (es) |
ES (1) | ES2568928T3 (es) |
HK (1) | HK1205739A1 (es) |
HR (1) | HRP20160415T1 (es) |
HU (1) | HUE027289T2 (es) |
IL (1) | IL233887A (es) |
IN (1) | IN2014DN06710A (es) |
MA (1) | MA35945B1 (es) |
ME (1) | ME02390B (es) |
MX (1) | MX353432B (es) |
MY (1) | MY171091A (es) |
NZ (1) | NZ629239A (es) |
PE (1) | PE20141972A1 (es) |
PH (1) | PH12014501963A1 (es) |
PL (1) | PL2822930T3 (es) |
RS (1) | RS54730B1 (es) |
SG (1) | SG11201404600VA (es) |
SI (1) | SI2822930T1 (es) |
SM (1) | SMT201600114B (es) |
TN (1) | TN2014000326A1 (es) |
TW (1) | TWI557112B (es) |
UA (1) | UA113641C2 (es) |
UY (1) | UY34654A (es) |
WO (1) | WO2013134085A1 (es) |
ZA (1) | ZA201405846B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009248945B2 (en) | 2008-05-23 | 2014-02-13 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
CA2753730C (en) | 2009-03-13 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
WO2013169531A1 (en) | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
TW201422592A (zh) * | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
EP2922835B1 (en) | 2012-11-21 | 2017-08-09 | Boehringer Ingelheim International GmbH | Process for making n-sulfinyl alpha-amino amides |
US10053453B2 (en) | 2014-10-07 | 2018-08-21 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
CA3057829A1 (en) * | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
EP3510029A4 (en) * | 2016-09-07 | 2020-03-11 | The Regents of The University of California | ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
CN113082209A (zh) * | 2021-03-31 | 2021-07-09 | 中国科学技术大学 | Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5745185A (en) | 1980-07-21 | 1982-03-13 | Eisai Co Ltd | Hydantoin derivative and its preparation |
CA2113818A1 (en) | 1991-08-28 | 1993-03-18 | Robert C. Gadwood | Spirocyclic benzopyran imidazolines |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
JP5020638B2 (ja) | 2003-12-15 | 2012-09-05 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼインヒビター |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
AU2005264915A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
EP1804794B1 (en) | 2004-10-13 | 2013-07-31 | Merck Sharp & Dohme Corp. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease |
EP1891021B1 (en) | 2005-06-14 | 2019-01-23 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
WO2007005404A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
BRPI0614576B1 (pt) | 2005-07-29 | 2017-05-30 | Koninklijke Philips Nv | dispositivo de passar a ferro a vapor |
KR20080050430A (ko) | 2005-09-26 | 2008-06-05 | 와이어쓰 | 베타-세크레타제 (bace) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물 |
BRPI0617852A2 (pt) | 2005-10-25 | 2011-08-09 | Shionogi & Co | compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
DE102005057688A1 (de) | 2005-12-01 | 2007-06-14 | Endress + Hauser Flowtec Ag | Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums |
BRPI0620025A2 (pt) | 2005-12-19 | 2011-10-25 | Wyeth Corp | composto, método para o tratamento de uma doença ou transtorno associado a atividade excessiva de bace, método para modular a atividade de bace, composição farmacêutica e uso do composto |
EP1974278A4 (en) | 2005-12-20 | 2012-01-04 | Fieldbus Foundation | SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS |
WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
AR061264A1 (es) | 2006-06-12 | 2008-08-13 | Schering Corp | Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih. |
SI2042480T1 (sl) | 2006-07-18 | 2013-08-30 | Astellas Pharma Inc. | Aminoindanski derivati ali njegova sol |
JP2010502705A (ja) | 2006-09-07 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療用としてのスピロピペリジンベータセクレターゼ阻害剤 |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
CL2008000784A1 (es) | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
AR065814A1 (es) | 2007-03-23 | 2009-07-01 | Wyeth Corp | Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados. |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
WO2008133273A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
EP2077637B1 (en) | 2007-12-12 | 2020-03-11 | Alcatel Lucent | System and method for protecting payload information in radio transmission |
BRPI0907563A2 (pt) | 2008-02-18 | 2015-08-04 | Hoffmann La Roche | Derivados de 4,5-di-hidro-xazol-2-il amina |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
PE20110805A1 (es) | 2008-09-11 | 2011-11-09 | Amgen Inc | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso |
MX2011005346A (es) | 2008-11-23 | 2011-06-16 | Pfizer | Lactamas como inhibidores de beta secretasa. |
CA2753730C (en) * | 2009-03-13 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2011072064A1 (en) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
CN102812005B (zh) | 2010-02-24 | 2014-12-10 | 生命医药公司 | β-分泌酶抑制剂 |
AR080865A1 (es) | 2010-03-31 | 2012-05-16 | Array Biopharma Inc | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
-
2013
- 2013-02-06 TW TW102104519A patent/TWI557112B/zh not_active IP Right Cessation
- 2013-03-04 UY UY0001034654A patent/UY34654A/es active IP Right Grant
- 2013-03-04 AP AP2014007900A patent/AP4029A/en active
- 2013-03-04 RS RS20160246A patent/RS54730B1/sr unknown
- 2013-03-04 MY MYPI2014002293A patent/MY171091A/en unknown
- 2013-03-04 US US13/784,032 patent/US8981112B2/en active Active
- 2013-03-04 SG SG11201404600VA patent/SG11201404600VA/en unknown
- 2013-03-04 PE PE2014001347A patent/PE20141972A1/es active IP Right Grant
- 2013-03-04 EP EP13710937.7A patent/EP2822930B1/en active Active
- 2013-03-04 JP JP2014560985A patent/JP6161643B2/ja not_active Expired - Fee Related
- 2013-03-04 NZ NZ629239A patent/NZ629239A/en not_active IP Right Cessation
- 2013-03-04 DK DK13710937.7T patent/DK2822930T3/en active
- 2013-03-04 AU AU2013230523A patent/AU2013230523B2/en not_active Ceased
- 2013-03-04 WO PCT/US2013/028796 patent/WO2013134085A1/en active Application Filing
- 2013-03-04 CN CN201380012529.9A patent/CN104271558B/zh not_active Expired - Fee Related
- 2013-03-04 CA CA2864143A patent/CA2864143C/en not_active Expired - Fee Related
- 2013-03-04 ES ES13710937.7T patent/ES2568928T3/es active Active
- 2013-03-04 HU HUE13710937A patent/HUE027289T2/en unknown
- 2013-03-04 UA UAA201410695A patent/UA113641C2/uk unknown
- 2013-03-04 BR BR112014021269A patent/BR112014021269A2/pt active Search and Examination
- 2013-03-04 IN IN6710DEN2014 patent/IN2014DN06710A/en unknown
- 2013-03-04 EA EA201491534A patent/EA024995B1/ru not_active IP Right Cessation
- 2013-03-04 KR KR1020147026838A patent/KR20140138774A/ko not_active Application Discontinuation
- 2013-03-04 ME MEP-2016-74A patent/ME02390B/me unknown
- 2013-03-04 PL PL13710937.7T patent/PL2822930T3/pl unknown
- 2013-03-04 MX MX2014010625A patent/MX353432B/es active IP Right Grant
- 2013-03-04 SI SI201330173A patent/SI2822930T1/sl unknown
- 2013-03-05 AR ARP130100706A patent/AR090241A1/es active IP Right Grant
-
2014
- 2014-07-30 IL IL233887A patent/IL233887A/en active IP Right Grant
- 2014-07-31 TN TNP2014000326A patent/TN2014000326A1/fr unknown
- 2014-08-08 ZA ZA2014/05846A patent/ZA201405846B/en unknown
- 2014-09-02 PH PH12014501963A patent/PH12014501963A1/en unknown
- 2014-09-02 CL CL2014002334A patent/CL2014002334A1/es unknown
- 2014-09-26 MA MA37375A patent/MA35945B1/fr unknown
- 2014-09-29 EC ECIEPI201420640A patent/ECSP14020640A/es unknown
- 2014-09-29 CO CO14215177A patent/CO7091177A2/es unknown
-
2015
- 2015-02-04 US US14/613,550 patent/US9526727B2/en active Active
- 2015-06-30 HK HK15106248.0A patent/HK1205739A1/zh not_active IP Right Cessation
-
2016
- 2016-04-19 CY CY20161100327T patent/CY1117543T1/el unknown
- 2016-04-19 SM SM201600114T patent/SMT201600114B/it unknown
- 2016-04-20 HR HRP20160415TT patent/HRP20160415T1/hr unknown
- 2016-12-19 US US15/383,287 patent/US9949975B2/en active Active
-
2017
- 2017-10-02 AU AU2017236042A patent/AU2017236042B2/en not_active Ceased
-
2018
- 2018-03-12 US US15/918,546 patent/US20180344734A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141972A1 (es) | Inhibidores de la beta-secretasa | |
BR112017010354A2 (pt) | compostos de triazolopirimidina e usos dos mesmos | |
CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CU20130101A7 (es) | Derivados de 1,4-oxazin-3-il-piridin-2-il-acetamida, activos como inhibidores bace-1 o bace-2 | |
ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
CO6801794A2 (es) | Derivados de isoxazolina en el tratamiento de ectoparasitos y su proceso de producción | |
PE20150669A1 (es) | Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1 | |
ECSP14013159A (es) | Compuestos inhibidores de metaloenzimas | |
TR201902788T4 (tr) | Nörodejeneratif hastalıkların tedavisinde kullanışlı 1-arilkarbonil-4-oksi-piperidin bileşikleri. | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
PE20150707A1 (es) | Inhibidores de la beta-secretasa | |
CR20140553A (es) | Compuestos de fenoxietil piperidina | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
EP2941255A4 (en) | METHOD FOR TREATING OR RELIEVING A DISEASE CAUSED OR AGGRAVATED BY MICROORGANISMS | |
EA201491581A1 (ru) | Везикулярные композиции | |
UY33973A (es) | Métodos de tratamiento dirigido de degeneración lobular frontotemporal. | |
WO2014052398A8 (en) | Inhibitors of beta-secretase | |
UA112146C2 (uk) | Спосіб отримання 4,1-бензоксатієпін-3-ону | |
TH1401003731A (th) | กระบวนการสำหรับการผลิตของ 1,3-บิวทาไดอีน | |
MX2014002343A (es) | Inhibidores de parp. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |